News Release

August 11, 2014
EMD Millipore Expands Manufacturing Capabilities in France with €12 Million Investment

- Investment to expand Ready-To-Use Media manufacturing
- Included Innovation Center to support and develop anticipated customer needs

August 11, 2014, Billerica, Massachusetts — EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced a €12 million investment in its Molsheim, France facility. This investment will expand EMD Millipore’s Ready-To-Use (RTU) Media manufacturing capabilities, better provide security of supplies for customers in the region, and sustain the heipha/Hycon product lines including contact and settle plates (ICRplus plates) and Agar strips for RCS® systems which are used in monitoring ambient air and compressed gases.

“We are committed to providing our customers with a reliable supply of products, including Ready-To-Use Media, which this investment in Molsheim will help to ensure,” said Udit Batra, President and CEO of EMD Millipore. “Both Molsheim and Eppelheim (Germany) sites will continue to support the increasing demand from our customers. This investment signifies our long-term dedication to EMD Millipore’s Lab customers in this region and around the world.”

This investment - which leverages our core-competencies in media development and experience in media production technology - includes the extension of the manufacturing capacity space for RTU Media, a new clean room, and two additional production lines similar to those existing in Eppelheim, where RTU Media will also continue to be manufactured. In addition, current research and development laboratories across various scientific areas of expertise will be centralized to form an Innovation Center to develop solutions for future customer needs.

EMD Millipore is a division of Merck KGaA, Darmstadt, Germany.
The increased manufacturing capacity will serve global market demand, and will ensure sufficient capacity to support the market growth. EMD Millipore acquired the heipha/Hycon product lines in 2011 as part of its purchase of Biotest AG which expanded the division’s offerings in industrial microbiology.

Molsheim has been an important location for EMD Millipore since the facility opened in 1972. Approximately 1,030 employees are based in Molsheim. In addition to ongoing R&D activities, this site manufactures products across EMD Millipore’s BioMonitoring, Lab Water, and BioPharm Process Solutions Business Fields.

About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Darmstadt, Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 66 countries and 2013 revenues of €2.6 billion.

EMD Millipore is a division of Merck KGaA, Darmstadt, Germany.